Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2022

Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2022

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. Once infused into the patient, these CARs enable the T-cells to recognize and attach to an antigen on the cancer cell, leading to its destruction.

Since the first historic CAR-T approvals in 2017, the following CAR T-cell therapies have achieved commercialization: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), and Abecma (idecabtagene vicleucel). Additionally, JW Therapeutics achieved NMPA approval of Relma-cel (relmacabtagene autoleucel) in China. This is the first CAR-T product independently developed in China and approved as a Category 1 biologics product, as well as the sixth approved CAR-T product globally.

In 2012, there were only 12 CAR-T clinical trials. Today, this number had surged to over 1,200. Based on CAR-T products in the clinical pipeline, the number of approved CAR-T cell therapies is projected to reach double digits within the next five years and over a 100 by 2035.This growth in the number of trials has been fueled by the unprecedented 90% remission rate shown in acute lymphoblastic leukemia (ALL) patients treated with Kymriah. From 60% to 70% of the patients treated in the earliest clinical trials are now in remission for more than nine years, which is an unprecedented accomplishment. The earliest approvals of Kymriah and Yescarta have been infused into an astounding half million patients worldwide.

These historic approvals demonstrate that the CAR-T market has arrived and is taking the biotech industry by storm. This has driven CAR-T funding to staggering new heights. At first the trend was subtle, but the tide has swelled as CAR-T start-ups have been richly funded by investors eager to get into this rapidly expanding area of regenerative medicine. In aggregate, there has been an astonishing $100 billion of market capitalization from CAR-T companies in recent years.

Financing rounds by CAR-T companies are approaching a total value of $4 billion, while CAR-T industry partnerships contribute an astounding $2 billion. M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead’s acquisition of Kite Pharma for $11.9 billion also made waves, as did other transactions, such as Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology for $665 million. The billion-dollar CAR-T cell therapy market would not have been possible without the remarkable efficacy of the early CAR-T therapies in treating several types of blood cancers. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

This 254-page report reveals:

CAR-T market size determinations with segmentation by product, geography, and indication, as well as future forecasts through 2027
Detailed coverage of the approved CAR-T products, including regulatory approvals, pricing, reimbursement, and market penetration
Clinical trial activity by type, geography, phase and sponsor
Comprehensive CAR-T patent analysis, including top inventors, patent holders, patent types, geographies, and most cited patents
CAR-T industry mergers and acquisitions, IPOs, and financing events
Deal-making, strategic partnerships, and co-commercialization agreements within the CAR-T sector
Little known market trends, future directions, and emerging opportunities
Profiles of 62 leading CAR-T competitors composing the global marketplace
And so much more

Although progressing at breakneck speed, developments within the field of CAR-T cell therapy are still early stage, positioning the market for remarkable expansion. Today is similar to the launch of the first chemotherapy treatments, when oncologists started treating patients with a single type of chemotherapy. Now, fifty years later, cancer patients are treated with over a hundred different chemotherapy agents. In the same way, we will soon have numerous CAR-T therapies available to treat liquid cancers, solid tumors, autoimmune diseases, inflammatory conditions, and beyond.
With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

About the Publisher

With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the cell therapy industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered near Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), U.S. FDA, Maryland Biotech Corridor, and policy makers on Capital Hill. Serving all-star clients that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in cell therapy industry data.